Xiangning Yuan Selected Research

5- methyl- 1- (3- fluorophenyl)- 2- (1H)- pyridone

1/2022	Fluorofenidone Inhibits UUO/IRI-Induced Renal Fibrosis by Reducing Mitochondrial Damage.
1/2021	Fluorofenidone protects liver against inflammation and fibrosis by blocking the activation of NF-κB pathway.
1/2020	Fluorofenidone Alleviates Renal Fibrosis by Inhibiting Necroptosis Through RIPK3/MLKL Pathway.
6/2018	Fluorofenidone attenuates interleukin-1β production by interacting with NLRP3 inflammasome in unilateral ureteral obstruction.
5/2018	[Effect of fluorofenidone on renal interstitial fibrosis in rats with unilateral ureteral obstruction].
11/2016	Fluorofenidone attenuates pulmonary inflammation and fibrosis via inhibiting the activation of NALP3 inflammasome and IL-1β/IL-1R1/MyD88/NF-κB pathway.
1/2014	Fluorofenidone offers improved renoprotection at early interventions during the course of diabetic nephropathy in db/db mice via multiple pathways.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiangning Yuan Research Topics

Disease

12	Fibrosis (Cirrhosis) 01/2022 - 07/2015
4	Ureteral Obstruction 01/2022 - 01/2017
3	Inflammation (Inflammations) 01/2021 - 11/2016
2	Necrosis 01/2020 - 11/2016
1	Reperfusion Injury 01/2022
1	Chronic Renal Insufficiency 01/2021
1	Endotoxemia 01/2021
1	Proteinuria 09/2020
1	Nephrotic Syndrome (Syndrome, Nephrotic) 09/2020
1	Pneumonia (Pneumonitis) 11/2016
1	Neoplasms (Cancer) 11/2016
1	Idiopathic Pulmonary Fibrosis 11/2016
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2014

Drug/Important Bio-Agent (IBA)

7	5- methyl- 1- (3- fluorophenyl)- 2- (1H)- pyridoneIBA 01/2022 - 01/2014
3	InflammasomesIBA 06/2018 - 07/2015
2	Long Noncoding RNAIBA 01/2021 - 01/2021
2	CollagenIBA 01/2021 - 01/2017
2	Fibronectins (Fibronectin)IBA 01/2021 - 01/2017
2	CytokinesIBA 01/2021 - 07/2015
2	Proteins (Proteins, Gene)FDA Link 05/2018 - 01/2017
2	salicylhydroxamic acid (SHAM)IBA 05/2018 - 01/2017
1	Mitochondrial DNA (mtDNA)IBA 01/2022
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2021
1	Dimethylnitrosamine (Nitrosodimethylamine)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Autophagy-Related ProteinsIBA 01/2021
1	Carbon Tetrachloride (Tetrachloromethane)IBA 01/2021
1	bailing capsulesIBA 09/2020
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2020
1	CaspasesIBA 01/2020
1	Messenger RNA (mRNA)IBA 05/2018
1	Platelet-Derived Growth FactorIBA 05/2018
1	Collagen Type I (Type I Collagen)IBA 05/2018
1	Collagen Type III (Type III Collagen)IBA 05/2018
1	Connective Tissue Growth FactorIBA 05/2018
1	CystathionineIBA 01/2017
1	NF-kappaB-Inducing KinaseIBA 11/2016
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 11/2016
1	InterleukinsIBA 11/2016
1	1- (4- ((3- (4- methylpiperazin- 1- yl)propyl)amino)benzyl)- 5- (trifluoromethyl)pyridin- 2(1H)- oneIBA 11/2016
1	PeroxiredoxinsIBA 11/2015
1	Interleukin-1beta (Interleukin 1 beta)IBA 07/2015

Therapy/Procedure

2	Therapeutics 01/2021 - 11/2015
1	Aftercare (After-Treatment) 09/2020